AU766595B2 - Chemokine receptor antagonist and cyclosporin in combined therapy - Google Patents

Chemokine receptor antagonist and cyclosporin in combined therapy Download PDF

Info

Publication number
AU766595B2
AU766595B2 AU61914/99A AU6191499A AU766595B2 AU 766595 B2 AU766595 B2 AU 766595B2 AU 61914/99 A AU61914/99 A AU 61914/99A AU 6191499 A AU6191499 A AU 6191499A AU 766595 B2 AU766595 B2 AU 766595B2
Authority
AU
Australia
Prior art keywords
cyclosporin
rantes
receptor antagonist
chemokine receptor
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU61914/99A
Other languages
English (en)
Other versions
AU6191499A (en
Inventor
Hermann-Joseph Grone
Peter J. Nelson
Amanda Proudfoot
Timothy N. C. Wells
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Applied Research Systems ARS Holding NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems ARS Holding NV filed Critical Applied Research Systems ARS Holding NV
Publication of AU6191499A publication Critical patent/AU6191499A/en
Application granted granted Critical
Publication of AU766595B2 publication Critical patent/AU766595B2/en
Assigned to LABORATOIRES SERONO SA reassignment LABORATOIRES SERONO SA Alteration of Name(s) in Register under S187 Assignors: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU61914/99A 1998-09-18 1999-09-16 Chemokine receptor antagonist and cyclosporin in combined therapy Ceased AU766595B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98117697A EP1000626A1 (en) 1998-09-18 1998-09-18 Chemokine receptor antagonist and cyclosporin in combined therapy
EP98117697 1998-09-18
PCT/EP1999/006844 WO2000016796A1 (en) 1998-09-18 1999-09-16 Chemokine receptor antagonist and cyclosporin in combined therapy

Publications (2)

Publication Number Publication Date
AU6191499A AU6191499A (en) 2000-04-10
AU766595B2 true AU766595B2 (en) 2003-10-16

Family

ID=8232654

Family Applications (1)

Application Number Title Priority Date Filing Date
AU61914/99A Ceased AU766595B2 (en) 1998-09-18 1999-09-16 Chemokine receptor antagonist and cyclosporin in combined therapy

Country Status (23)

Country Link
US (1) US6902728B1 (enExample)
EP (2) EP1000626A1 (enExample)
JP (1) JP2003519082A (enExample)
KR (1) KR100613950B1 (enExample)
CN (1) CN1177613C (enExample)
AR (1) AR021810A1 (enExample)
AT (1) ATE227582T1 (enExample)
AU (1) AU766595B2 (enExample)
BR (1) BR9913846A (enExample)
CA (1) CA2344370A1 (enExample)
DE (1) DE69903964T2 (enExample)
DK (1) DK1113811T3 (enExample)
EA (1) EA003181B1 (enExample)
EE (1) EE04705B1 (enExample)
ES (1) ES2186411T3 (enExample)
HK (1) HK1041225B (enExample)
IL (2) IL141899A0 (enExample)
NO (1) NO20011371D0 (enExample)
PT (1) PT1113811E (enExample)
SI (1) SI1113811T1 (enExample)
UA (1) UA60379C2 (enExample)
WO (1) WO2000016796A1 (enExample)
ZA (1) ZA200101909B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7259136B2 (en) 1999-04-30 2007-08-21 Amylin Pharmaceuticals, Inc. Compositions and methods for treating peripheral vascular disease
US6740636B2 (en) 2000-07-31 2004-05-25 Schering Aktiengesellschaft Non-peptide CCR1 receptor antagonists in combination with cyclosporin A for the treatment of heart transplant rejection
LT5132B (lt) 2000-07-31 2004-05-25 Schering Aktiengesellschaft Nepeptidiniai ccr1 receptorių antagonistai derinyje su ciklosporinu a širdies transplanto atmetimui gydyti
MX2010001307A (es) 2007-08-02 2010-07-30 Novimmune Sa Anticuerpos anti-proteína regulada con la activación, expresada y secretada por los linfocitos t normales y metodos de uso de los mismos.
JP6733968B2 (ja) * 2015-08-31 2020-08-05 日立化成株式会社 腎移植後合併症を評価するための分子法
JP6624704B2 (ja) 2015-08-31 2019-12-25 日立化成株式会社 尿路上皮疾患の評価のための分子法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997005896A1 (en) * 1995-08-09 1997-02-20 Schering Corporation Combined use of interleukin-10 and cyclosporin for immunosuppression therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2207036A1 (en) * 1994-12-08 1996-06-13 Glaxo Group Limited Rantes peptide and fragments and compositions comprising it for treatment of inflammation
EP0927167A1 (en) * 1996-08-14 1999-07-07 Warner-Lambert Company 2-phenyl benzimidazole derivatives as mcp-1 antagonists
WO1998006751A1 (en) * 1996-08-16 1998-02-19 Research Corporation Technologies, Inc. Mcp-3, rantes and mip-1alpha receptor antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997005896A1 (en) * 1995-08-09 1997-02-20 Schering Corporation Combined use of interleukin-10 and cyclosporin for immunosuppression therapy

Also Published As

Publication number Publication date
EA003181B1 (ru) 2003-02-27
DE69903964T2 (de) 2003-03-27
SI1113811T1 (en) 2003-04-30
CA2344370A1 (en) 2000-03-30
CN1177613C (zh) 2004-12-01
EP1000626A1 (en) 2000-05-17
ZA200101909B (en) 2001-09-11
IL141899A0 (en) 2002-03-10
WO2000016796A1 (en) 2000-03-30
JP2003519082A (ja) 2003-06-17
ES2186411T3 (es) 2003-05-01
HK1041225A1 (en) 2002-07-05
NO20011371L (no) 2001-03-16
UA60379C2 (uk) 2003-10-15
IL141899A (en) 2007-12-03
AU6191499A (en) 2000-04-10
US6902728B1 (en) 2005-06-07
EP1113811B1 (en) 2002-11-13
HK1041225B (zh) 2005-04-22
KR100613950B1 (ko) 2006-08-18
KR20010075060A (ko) 2001-08-09
AR021810A1 (es) 2002-08-07
PT1113811E (pt) 2003-03-31
EE04705B1 (et) 2006-10-16
EA200100366A1 (ru) 2001-08-27
EP1113811A1 (en) 2001-07-11
EE200100159A (et) 2002-08-15
BR9913846A (pt) 2001-06-05
ATE227582T1 (de) 2002-11-15
DK1113811T3 (da) 2003-03-10
CN1319021A (zh) 2001-10-24
DE69903964D1 (en) 2002-12-19
NO20011371D0 (no) 2001-03-16

Similar Documents

Publication Publication Date Title
Gröne et al. Met‐RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment
Murai et al. Active participation of CCR5+ CD8+ T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease
Maas et al. Endothelial cell PECAM-1 confers protection against endotoxic shock
Yin et al. SDF-1α involved in mobilization and recruitment of endothelial progenitor cells after arterial injury in mice
US20020018776A1 (en) Method of treating graft rejection using inhibitors of CXCR3 function
Suzuki et al. Susceptibility to T cell-mediated injury in immune complex disease is linked to local activation of renin-angiotensin system: the role of NF-AT pathway
WO2001078653A2 (en) Graft rejection inhibition with ccr2 inhibitors
EP1113811B1 (en) Chemokine receptor antagonist and cyclosporin in combined therapy
US5675062A (en) Cellular basis of transplant arteriosclerosis in mice
US20020019345A1 (en) Method of treating graft rejection using inhibitors of CCR5 function
EP2063908B1 (en) Use of modified interleukin-8 proteins for treating reperfusion injury or transplant rejection
WO2001002003A1 (en) Method of treating psoriasis with il-15 antagonist
EP1671648A1 (en) Prevention and treatment for gvhd
Guth et al. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo
SHIRwAN et al. Prevention of orthotopic liver allograft rejection in rats with a short-term brequinar sodium therapy: Analysis of intragraft cytokine gene expression
MXPA01002838A (en) Chemokine receptor antagonist and cyclosporin in combined therapy
AU2862300A (en) Methods for preventing graft rejection and ischemia-reperfusion injury
Leeuwenberg et al. Soluble tumor necrosis factor-receptors are not a useful marker of acute allograft rejection: a study in patients with renal or cardiac allografts
Gerlach et al. Systemic liberation of interleukin-8 in the perioperative phase of liver transplantation
AU2021227451A1 (en) Compositions and methods
Okumura et al. Susceptibility to T Cell-Mediated Injury in
Redl et al. The Role of TNF in Gram-Negative Sepsis in Baboon
MXPA01007564A (en) Methods for preventing graft rejection and ischemia-reperfusion injury

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)